March 29, 2020

Actinic Keratosis Market | Key Players are Tolmar Pharmaceuticals Inc, DUSA Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Aqua Pharmaceuticals and others.

According to the latest report published by Credence Research, Inc. “Actinic Keratosis Market – Growth, Future Prospects and Competitive Analysis, 2016-2022,” the market for actinic keratosis was valued at USD 6.561.8 million in 2015 and is expected to reach USD 8.909.7 million by 2022, with the market growing at CAGR 4.35 per cent from 2016-2022.

Market Insights

Actinic keratosis (AK) is characterized by skin papules, macules or plaques resulting from prolonged exposure to harmful UV and may result in squamous cell carcinoma. The risk of developing actinic keratosis increases with increasing age and is particularly higher in both men and women. Approximately 5-20 percent of patients with actinic keratosis develop malignant and potentially fatal squamous cell carcinomas.

Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/actinic-keratosis-market

Destructive therapies such as liquid nitrogen cryotherapy and surgical therapy are the gold standard for AK therapy among the various treatment methods available. Cryotherapy was the most commonly sought treatment by clinicians in 2015. However, improved clinical results of photodynamic therapy and a growing preference for drug-device combination therapy have encouraged both caregivers and patients to opt for novel treatment methods that offer both advanced efficacy, esthetic benefits and reduced risk of future malignancies.  Topical treatment is a prolonged treatment and is comparatively more effective than other treatments, but patient compliance is a key issue that hinders the growth of this segment. Photodynamic therapy is the fastest growing treatment over the forecast period due to increasing demand for non-invasive surgery, and fewer treatment sessions are the key factors expected to help this market North America is the largest market for actinic keratosis therapy due to increasing prevalence of AK, better public awareness of AK and associated risk of squamous cell ca. According to the American Academy of Dermatology (AAD), approximately 60 percent of Americans 40 years of age or older are predisposed to develop at least 1 AK lesion. Actinic keratosis is a precursor to squamous cell cancer. The U.S. held the largest market share in actinic keratosis in 2015 due to the current prevalence of actinic keratosis in the region. Asia Pacific is the fastest growing market for AK treatments. Australia has the highest prevalence of actinic keratosis in the adult population, ranging from 40% to 60%. Growing regional awareness and rapid development of healthcare infrastructure and expenditure are key growth factors in the Asian Pacific market for actinic keratosis.

This market is mainly driven by the large presence of generic drugs and is moderately competitive. The market for photodynamic therapy has developed a niche containing methyl aminolevulinate and aminolevulinic acid. Galderma and Dusa Pharmaceuticals are the main players in this area.

Some of the major players in the global actinic keratosis market are Tolmar Pharmaceuticals, Inc, DUSA Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC, Galderma SA, Perrigo Company plc, LEO Laboratories, Apotex and others.

Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/58011

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

Market Segmentation

By Treatment Type

  • Destructive  Treatment
    • Liquid Nitrogen Cryotherap
    • Surgical Therapy
  • Photodynamic Therapy
    • 5-aminolevulinic acid (ALA)
    • methyl aminolevulinate (MAL)
  • Topical Medications
    • 5-fluorouracil (5-FU)
    • Imiquimod
    • Ingenolmebutate
    • Diclofenac Sodium
  • Chemical Peel and Others

By Geography Segment

  • North America (the U.S., Rest of North America)
  • Europe (U.K., Germany, France, Rest of Europe)
  • Asia Pacific (China, Japan, India, Rest of Asia Pacific)
  • Rest of World (Middle East & Africa (MEA), Latin America)

Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/58011

Leave a Reply

Your email address will not be published. Required fields are marked *